Indeed, IFNα treatment in the context of multiple sclerosis and chronic myeloid leukemia has been associated with neurotoxicity, which is in contrast to IFNβ that is used for the treatment of multiple sclerosis [49,50]. The gene discussed is IFNA17; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.